摘要
目的瑞舒伐他汀是目前经临床试验证实能够稳定并逆转动脉粥样硬化病变进展的他汀类药物,本实验主要探讨药物干预后基质金属蛋白酶(MMP)-2,9在动脉粥样硬化斑块稳定中的机制。方法人单核细胞株(THP-1)经佛波酯(PMA)诱导贴壁为巨噬细胞后,利用氧化型低密度脂蛋白(ox-LDL)80mg/L与巨噬细胞共同孵育,分别给予不同药量(0,2,4,7和10ng/ml)的瑞舒伐他汀进行干预,应用RT-PCR法检测上述组细胞中MMP-2,MMP-9mRNA表达结果;应用ELISA的方法检测各实验组的上清液中MMP-2、MMP-9的表达。结果 7、10ng/ml瑞舒伐他汀可以使MMP-2和MMP-9的蛋白表达量和mRNA的表达与其对照组相比均有显著性差异(P<0.01),无论是蛋白表达还是mRNA的表达均具有随药物浓度的增加而降低的趋势。结论瑞舒伐他汀可以降低MMP-2和MMP-9在THP-1源性巨噬细胞中的表达,这有利于动脉粥样硬化斑块的稳定。
Objective Rosuvastatin is the statins that can reverse the coronary atherosclerotic lesions documented by clinical trials.This experiment mainly discussed the mechanism of metal matrix protein enzymes in stabilizing atherosclerotic plaque after rosuvastatin intervention.Methods After people mononuclear cell lines(THP-1)induced by phorbol(PMA)and adherenced,using oxidation type low density lipoprotein(ox-LDL)80 mg/L and macrophages common incubation,treated by different doses of rosuvastatin(0,2,4,7,and 10 ng/ml),separately.RT-PCR method was used to detect the expression of MMP-2,MMP-9 mRNA in each group cell.ELIAS was used to detect the expression of MMP-2,MMP-9 in liquid supernatant of each group.Results There was significant difference of the quantity of MMP-2 and MMP-9 protein expression and the expression of the mRNA between the group treated by 7,10 ng/ml rosuvastatin and control group(P<0.01).The protein expression and mRNA expression both reduced with the increasing of the concentration of the rosuvastatin.Conclusions Rosuvastatin can reduce the expression of MMP-2 and MMP-9 in THP-1 source sex macrophages,which is conducive to the stability of the atherosclerotic plaque.
出处
《中华临床医师杂志（电子版）》
CAS
2012年第16期4642-4645,共4页
Chinese Journal of Clinicians(Electronic Edition)
